Minimal residual disease in acute myeloid leukaemia

被引:17
作者
Yin, JAL [1 ]
机构
[1] Univ Manchester, Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England
关键词
MRD; AML; AML-MTG8; CBFB-MYHII; WTI; multiparameter flow cytometry; qualitative; quantitative; real-time; RT-PCR;
D O I
10.1053/beha.2002.0188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relapse remains the main cause of treatment failure in acute myeloid leukaemia (AML). Studies to date suggest that monitoring of minimal residual disease (MRD) in AML is useful in identifying patients at high risk of relapse from those in durable remission. This chapter describes the methodological advances in the detection of MRD and, in particular, focuses on the development of highly sensitive RT-PCR techniques, including real-time, for quantifying MRD. Preliminary results on the clinical utility of MRD monitoring in AML with t(8;21) and inv(16) are promising and provide the basis for further evaluation by quantitative real-time analysis in prospective clinical trials. For AML without a specific fusion transcript, the WTI gene is an alternative molecular target. The clinical value of quantitative MRD monitoring in AML, however, will need to be confirmed in future studies.
引用
收藏
页码:119 / 135
页数:17
相关论文
共 83 条
  • [1] High frequency of immunophenotype changes in acute myeloid leukemia at relapse:: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
    Baer, MR
    Stewart, GC
    Dodge, RK
    Leget, G
    Sulé, N
    Mrózek, K
    Schiffer, CA
    Powel, BL
    Kolitz, JE
    Moore, JO
    Stone, RM
    Davey, FR
    Carrol, AJ
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2001, 97 (11) : 3574 - 3580
  • [2] High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
    Bergmann, L
    Miething, C
    Maurer, U
    Brieger, J
    Karakas, T
    Weidmann, E
    Hoelzer, D
    [J]. BLOOD, 1997, 90 (03) : 1217 - 1225
  • [3] BETTS DR, 1992, LEUKEMIA, V6, P1250
  • [4] Loss of the DEK-CAN fusion transcript in a child with t(6;9) acute myeloid leukemia following chemotherapy and allogeneic bone marrow transplantation
    Boer, J
    Mahmoud, H
    Raimondi, S
    Grosveld, G
    Krance, R
    [J]. LEUKEMIA, 1997, 11 (02) : 299 - 300
  • [5] BUOHAMIC I, 2000, BLOOD S, V96, pA312
  • [6] DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE
    CAMPANA, D
    PUI, CH
    [J]. BLOOD, 1995, 85 (06) : 1416 - 1434
  • [7] Cilloni D, 2000, BLOOD, V96, p500A
  • [8] CLAXTON DF, 1994, BLOOD, V83, P1750
  • [9] Costello R, 1997, BLOOD, V89, P2222
  • [10] COUSTANSMITH E, 1993, LEUKEMIA, V7, P853